NDAORALSOLUTIONPriority Review
Approved
Nov 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Clinical Trials (5)
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Started Sep 2025
150 enrolled
TuberculosisHIV
Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)
Started Jul 2025
50 enrolled
HIVHIV-1
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
Started Sep 2024
40 enrolled
HIV-1-infectionOpioid Use Disorder
A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)
Started Feb 2024
20 enrolled
Healthy
HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil
Started Sep 2023
2,500 enrolled
HIVDrugResistance